Immunotherapy has firmly established itself as a compelling avenue for treating disease. Although many clinically approved immunotherapeutics engage the adaptive immune system, therapeutically targeting the innate immune system remains much less explored. Nanomedicine offers a compelling opportunity for innate immune system engagement, as many nanomaterials inherently interact with myeloid cells (e.g., monocytes, macrophages, neutrophils, and dendritic cells) or can be functionalized to target their cell-surface receptors. Here, we provide a perspective on exploiting nanomaterials for innate immune system regulation. We focus on specific nanomaterial design parameters, including size, form, rigidity, charge, and surface decoration. Furthermore, we examine the potential of high-throughput screening and machine learning, while also providing recommendations for advancing the field. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
|Number of pages||22|
|Journal||Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology|
|Early online date||13 Apr 2021|
|Publication status||Published - Nov 2021|
Bibliographical noteFunding Information:
The authors thank the Icahn School of Medicine at Mount Sinai. This work was supported by the National Institutes of Health (NIH) grants R01 CA220234, R01 HL144072, P01 HL131478, and NWO/ZonMW Vici 91818622 (W.J.M.M.).
© 2021 Wiley Periodicals LLC.
Copyright 2021 Elsevier B.V., All rights reserved.
- innate immunotherapy